Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: A multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial
Matti J. Välimäiki, Jordi Farrerons-Minguella, Johan Halse, Heikki Kröger, Marilyn Maroni, Henk Mulder, Manuel Muñoz-Torres, Maria Sääf, Erik Snorre ØfjordVolume:
29
Year:
2007
Language:
english
Pages:
1950
DOI:
10.1016/j.clinthera.2007.09.017
File:
PDF, 1.90 MB
english, 2007